Early RA Referral Clinics Work (9.18.2026) Save

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

1. 4,197 pts from the UK Biobank met fibromyalgia criteria, yet 72.6% had NOT received a diagnosis. Non-Dx assoc w/ male, older age, milder sxs or other pain Dx (OA, CRPS, CFS), lower polysymptomatic distress scores, and less frequent fatigue. https://t.co/Y9m9jR5wbR
2. OL study of tofacitinib in 20 juvenile DM pts w/ calcinosis cutis (11 boys; age 10.4 yrs; CC x 31 mos). Calcinosis assessed by CT scan showed decr Agatston score from 6,349 to 4,007. No SAE. https://t.co/UDLLwce3mp
3. TriNetX retrospective EHR study showed VTE in #RA not incr by taking JAKi. Pts undergoing THA/TKA Rx w/ JAKi (n 284) vs TNFi (n 288). VTE- 17 JAKi (6%) vs 11 TNFi (3.8%)- nonsignif incr (RR 1.57) https://t.co/OM5ipieQtr
4. FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis. Regulatory decision expected 1st quarter 2027. Supported by phase 3 RCTs, 3000 pts -- LATITUDE PsO 3001 and 3002 clinical trials. https://t.co/o7oqxSXHSw
5. Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome. Pacritinib (Vonjo) is a kinase inhibitor (JAK2, FLT3) that is approved to treat adults with intermediate or high-risk myelofibrosis https://t.co/V7duJPyJpG
6. Metanalysis of 87 studies shows predictors of #MTX response: early Dz, low dz activity, early MTX initiation, and absence of erosive disease. Smoking and higher BMI were linked to reduced efficacy. https://t.co/OfB09aHNOS
7. Indian study of 85 #RA pts in LDA or better (DAS28-ESR ≤ 3.2). W/ 6 mos F/U, 39 (46%) had 1+ RA flare (DAS28 > 3.2); time to flare 12 wks (8–18) unrelate to Dz activity. Predictors: seropositivity (HR 2-2.3) https://t.co/ifqeoPtxpx https://t.co/ltx64X55fd
8. Single center study of FALLs in 124 ambulatory RA females ≥50 yrs.(age 68 yrs, DAS28 2.6, sarcopenia 16%, prior fall 25%). 27.4% had falls; predicted by prior fall hx (OR 2.76, hypnotics/anxiolytics (3.92), not steroids or sarcopenia (NS trend) https://t.co/J62RPF9rQs
9. Metanalysis 11 studies & 104277 gout & hyperuricemic pts shows erectile dysfunction is signif. increased (RR1.37; 1.14-1.65) related to lower testosterone & estradiol. Other factors: obesity, age, DM, CVD. https://t.co/1ufih2E3UN
10. Chinese 52 wk study of XKH004, a novel, SC, humanized anti-17A/F in 323 active AS pts Rx q4 wks vs PBO. @ Wk 16, XKH004 was superior for ASAS40 (45.4% vs 19.4%; P<0.001), improved to 66% by wk 52. https://t.co/f7w41m4QZy
11. In 2022, Overweight & obesity affect 65.8% of Swiss PsA pts (vs gen pop.= 43%) and has increased since 2007. Obesity was assoc w/ elevated CRP (56% vs 37%), Inc Pt global assess (3.2 vs 2.8), & MD global (2.5 vs 2.1) & lower EQ-5D-3L(0.7 vs 0.8). https://t.co/xPoy4dgvlD
12. Data presented at 2027 ASMBS meeting showed betw 2020-2024, wt loss surgeries dropped 23%, from 230,000 in 2022 to 177,000 in 2024. Less than 1% of eligible pts are now having weight-loss surgery https://t.co/UnYIIBDdnz
13. JAMA Surgery analysis showed that between 2022-2024 bariatric surgery fell 34.1%, While GLP-1 use rose more than 140% over the same period. (SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults without diabetes.) https://t.co/s3NRFY2R5w
14. Discussing Weight Loss: 3 Minute Script Dr. Jack Cush's 3 Minute Script as discussed in his Introducing Weight Loss video. https://t.co/JRWAPc5if5
15. Together PsA 52 wk data (n 271): ACR50 plus >10% wt loss - 39.2% w/ Taltz & Zepbound vs 1.7% w/ Taltz alone. Together PsO trial results (n 274): PASI100 plus >10% wt loss - 30.6% w/ Taltz & Zepbound vs 4.4% w/ Taltz alone. https://t.co/27TBZyL8l1
16. Waist size matters! Using NHANES data (1999-2018) the weight-adjusted waist index (WWI) calculated on 5582 CKD pts. WWI was signif assoc w/ all-cause mortality (adj HR 1.17) & CV (1.24); these assoc partially mediated by NLR (inflammation) ~6.6%, showing both central adiposity https://t.co/kNf4nqiD2a
17. Early RA Referral Clinics Work!
18. Added IVIG is Effective in Myositis
19. RheumIQ quiz athttps://t.co/UaXqHKWizt
20. Registration opens October 1 for RheumNow.Live 2027